Mango Sciences, Inc., the Boston, US, and Bengaluru, IN-based data and AI company, announced a strategic partnership with ImmunoAdoptive Cell Therapy (ImmunoACT), the Mumbai, India-based pioneering cell and gene therapy development company, to expand access and affordability of ImmunoACT’s NexCAR19^TM chimeric antigen receptor T-cell (CAR-T) for leukaemia and lymphoma. The partnership enables patients to avail easy 0% interest EMI plans of up to 10 lakhs to cover the cost of CAR-T. Additionally, a value-based offering of up to ₹10 lakhs can also be availed by clinically eligible patients.

NexCAR19^TM is a first-of-its-kind product that has given patients in India access to this lifesaving, leading-edge therapy at an affordable price, and this partnership is aimed at making this treatment accessible for more patients. The Mango Sciences plan benefit will be available initially at select health care facilities to patients who take NexCAR19^TM.

“We are excited to bring our Value-Based offerings to CAR-T - a global first. We aim to utilise data science and technology to ensure patients can access the latest innovations in oncology. Together with ImmunoACT, we are committed to improving access to innovative treatments, such as CAR-T, to improve the paradigm of cancer outcomes.” Dr Mohit Misra, Founder & CEO of Mango Sciences.

Dr Rahul Purwar, Founder ImmunoACT, states, “We are delighted to partner with Mango to improve access & affordability for patients who need NexCAR19. The programs shall significantly help patients to afford our therapy, and are outcome-based, demonstrating our conviction and evidence of NexCAR19’s efficacy and safety.”